news, journals and articles from all over the world.
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
NCCN announces a renewed collaboration with LACOG to publish new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer: Brazil Edition. Additional Brazilian adaptations of NCCN Guidelines for other cancer types are planned for the future.
The findings, published in the Journal of the National Cancer Institute, show that markers of cellular aging—such as DNA damage response, cellular senescence, and inflammatory pathways—significantly increased in all breast cancer survivors, regardless of the type of treatment received.
The University of Texas MD Anderson Cancer Center today announced an agreement to become a Women’s Cancer Partner with the Union for International Cancer Control (UICC), marking a significant collaboration to improve breast and cervical cancer care worldwide.
Key mechanism of resistance to BRAF-targeted melanoma therapy discovered. Potential for developing new cancer therapies with high efficacy by regulating polyamine biosynthesis to suppress resistance.
Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James and Richard J. Solove Research Institute are trying to improve outcomes for patients with a deadly form of brain cancer known as glioblastoma.
A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy if administered earlier in the treatment cycle, according to a study from Vanderbilt researchers.
For years, cancer researchers have noticed that more men than women get a lethal form of brain cancer called glioblastoma. They’ve also found that these tumors are often more aggressive in men. But pinpointing the characteristics that might help doctors forecast which tumors are likely to grow more quickly has proven elusive.
A research team at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. The findings were published today in the journal Cell.
In two new papers, both published in Cell Reports Medicine, researchers from the University of Michigan Rogel Cancer Center describe the mechanisms of how alterations in the CDK12 gene drive prostate cancer development and report on a promising degrader that targets CDK12 and a related gene to destroy tumors.
Houston Methodist researchers will be part of a national consortium funded by an up to $49 million award from the U.S. Government’s Advanced Research Projects Agency for Health (ARPA-H) to develop a vaccine against two of the most common and destructive strains of herpesviruses that latently infect a majority of Americans and can lead to acute infections, multiple forms of cancer, autoimmune disease and birth defects.
Houston Methodist researchers have developed an advanced mathematical model that predicts how novel treatment combinations could significantly extend progression-free survival for patients with non-small-cell lung cancer (NSCLC), the most common type of lung cancer.
“5 Things I Learned About Cancer From My Diagnosis” – Journalist Rochelle Broder-Singer offers tips learned from her experience as a breast cancer survivor.
A new way of diagnosing lung cancer with a blood draw is 10 times faster and 14 times more sensitive than earlier methods, according to University of Michigan researchers.
Los cambios precancerosos en las células del esófago, una condición conocida como esófago de Barrett, son un factor de riesgo para el cáncer de esófago. El esófago de Barrett es causado por la enfermedad por reflujo gastroesofágico (ERGE), que ocurre cuando el ácido del estómago regresa constantemente al esófago, irritando el revestimiento del esófago.
As alterações pré-cancerosas nas células do esôfago, uma condição conhecida como esôfago de Barrett, são um fator de risco para o câncer de esôfago. O esôfago de Barrett é causado pela doença do refluxo gastroesofágico (DRGE), que ocorre quando o ácido do estômago retorna constantemente para o esôfago, irritando o revestimento do esôfago.
فينيكس، ولاية أريزونا — تُعد التغيرات في خلايا المريء السابقة للتسرطن، وهي حالة تُسمى مريء باريت، من عوامل الخطورة المرتبطة بسرطان المريء. وينتُج داء باريت عن داء الارتجاع المَعِدي المريئي الذي يحدث عندما يتكرر ارتداد حمض المعدة إلى المريء مما يؤدي إلى تهيج بطانته.
SEATTLE – Oct. 2, 2024 – Four National Cancer Institute-designated cancer centers – Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins – have joined forces and secured funding from AI technology leaders AWS, Deloitte, Microsoft and NVIDIA, to create the Cancer AI Alliance (CAIA).
Radiation therapy techniques have been used for more than a century to treat cancers. Physicists in the Radiation Detector and Imaging group and associated with the Biomedical Research & Innovation Center (BRIC) at Jefferson Lab are launching a study into how best to advance safer types of radiation therapy. BRIC scientists plan to evaluate the ability of accelerator-based proton therapy to replace radioactive isotope-derived treatments.
A Cleveland Clinic-led research collaboration between Timothy Chan, MD, PhD, Chair of Cleveland Clinic’s Global Center for Immunotherapy, and Bristol Myers Squibb has published the most comprehensive overview to date of how our immune system reshapes tumor architecture in response to immune checkpoint therapy.
The eight-year study, published in Nature Medicine, outlines how cancer immunotherapy induces tumor recognition through neoantigens to reshape the tumor ecosystem.
Cancer cells frequently overhaul their surroundings, making tumors stiffer than nearby healthy tissue. While tumor stiffening makes some cancers easier to detect — this is why physicians feel for hard lumps in the body — it can also ramp up tumor growth and drug resistance. New research suggests that these detrimental changes are not set in stone, however.
Researchers at McMaster University have identified a new therapeutic approach to preventing cancer from spreading to the brain.
The American Cancer Society (ACS) today released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. However, not all women have benefited from this progress, notably American Indian and Alaska Native (AIAN) women, whose rates have remained unchanged over the past three decades
The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).
A new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool.
Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds.
An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
A team of researchers from NUS Institute for Health Innovation & Technology (iHealthtech), led by Associate Professor Shao Huilin and Associate Professor Brian Lim, has developed a first-of-its-kind technology to map out diverse protein interactions in cells using DNA barcodes.
The technology, dubbed TETRIS, can explicitly identify and quantify multiple interacting partners in large protein assemblies. By capturing the complex hierarchy of protein interactions within tumour cells, the technology uncovers detailed molecular mechanisms driving disease progression. This enables more precise diagnostics, allowing for the accurate sub-typing of cancers and the identification of aggressive forms of the disease in just a few hours, which was not possible previously.
Analysis of three large, phase III clinical trials finds more than 40% of brain metastases patients completely reversed cognitive losses
A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Abstract Background Proton therapy (PT) has potential advantages in pediatric Hodgkin lymphoma (pHL). However, there are limited data on PT, specifically to infradiaphragmatic targets. We report on PT planning details, doses achieved to organs at risk (OARs), and clinical and…
In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium. This groundbreaking initiative aims to eradicate inequities for children, adolescents, and young adults diagnosed with cancer or blood disorders via the rapid development and evaluation of policy-relevant, evidence-based and community informed health equity interventions.
Pesquisadores da Mayo Clinic investigaram as bases moleculares do câncer e descobriram uma nova razão pela qual o receptor de antígeno quimérico (terapia com células CAR-T) não funciona em alguns pacientes. Essa descoberta estimulou novas estratégias que incorporam anticorpos e edição genética para melhorar os resultados desse tratamento inovador para os pacientes. Esta pesquisa do Dr. Saad Kenderian, consultor em hematologia da Mayo Clinic, foi publicada na Nature Communications.
Investigadores de Mayo Clinic investigaron las bases moleculares del cáncer y descubrieron una nueva razón por la cual el receptor de antígeno quimérico (terapia con células CAR-T) no funciona en algunos pacientes. Este hallazgo estimuló nuevas estrategias que incorporan anticuerpos y edición genética para mejorar los resultados de este tratamiento innovador para los pacientes. Esta investigación del Dr. Saad Kenderian, consultor en hematología de Mayo Clinic, fue publicado en Nature Communications.
روتشستر، ولاية مينيسوتا — توصل باحثو مايو كلينك إلى الأسس الجزيئية للسرطان واكتشفوا سببًا جديدًا لفشل مستقبلات المستضد الخيمرية (العلاج بالخلايا التائية) مع بعض المرضى. وقد عزز هذا الاكتشاف وضع استراتيجيات جديدة تدمج الأجسام المضادة وتعديل الجينات لتحسين نتائج هذا العلاج المتقدم للمرضى. نُشر هذا البحث الذي أجراه سعد كينديريان، بكالوريوس الطب والجراحة، استشاري طب الدمويات في مايو كلينك، في مجلة نيتشر كوميونيكيشنز (Nature Communications).
Comprehensive gene panel testing, one of the exciting new tools in cancer diagnostics, warrants greater scrutiny — as does a federal program aimed at speeding up the review process for proposed new medical technologies. Those are conclusions of Yale medical experts who studied both and published a report in the Journal of the National Cancer Institute on Sept.
The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert is quoted explaining the results.
Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on the findings were reported in the September 20 online issue of European Urology [https://doi.org/10.1016/j.eururo.2024.07.013].
Scientists from the American Cancer Society (ACS) are presenting research studies at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) Quality Care Symposium (QCS) September 27-28 in San Francisco, CA.
UCLA investigators have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer. The results, which were recently published in JAMA Oncology, show potential to broaden the number of patients with bladder cancer who could benefit from immunotherapy, an approach that harnesses a patient’s own immune system to fight cancer.
Highly vulnerable patients treated at hospitals accredited by the ACS Commission on Cancer were more likely to receive guideline-based care and less likely to die.
Zhijian “James” Chen, Ph.D., Professor of Molecular Biology and Director of the Center for Inflammation Research at UT Southwestern Medical Center, has been awarded the Albert Lasker Basic Medical Research Award for his discovery of the cGAS enzyme.
Case Western Reserve University and the Louis Stokes Cleveland VA Medical Center have been awarded a $1.14M grant from the U.S. Department of Veterans Affairs to use artificial intelligence (AI) to determine the best personalized treatment for Veterans with rectal cancer.
Os tratamentos para os cânceres no sangue estão evoluindo, oferecendo mais opções às pessoas que vivem com a doença.
Los tratamientos para los cánceres de la sangre están evolucionando, ofreciendo más opciones a las personas que viven con la enfermedad.
روتشستر، ولاية مينيسوتا — يتطور علاج سرطانات الدم باستمرار، ما يتيح المزيد من الخيارات العلاجية للأشخاص المصابين بالمرض.
Pink Fund is proud to be a partner in the latest study from Northwestern Medicine that, for the first time, uses patient input on how they would like to be screened for financial needs.
Ovarian cancer is often called the “silent killer”. Most of the time it has no symptoms in its early stages. By the time symptoms appear, the cancer may have already spread. This is why regular screenings are so important. Eugene…
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu